RACHEL SCHUELLER: Open Payments
NPI 1235887787 · CHANDLER, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,453 in 65 payments from 14 companies in 2025. Trend: 2023 $870 · 2024 $532 · 2025 $1,453
Food & beverage: $1,453
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 11 | $226 |
| Novartis Pharmaceuticals Corporation | 13 | $225 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $173 |
| GENZYME CORPORATION | 6 | $168 |
| AstraZeneca Pharmaceuticals LP | 3 | $163 |
| Optinose US, Inc. | 5 | $100 |
| Genentech USA, Inc. | 3 | $88 |
| Grifols USA, LLC | 3 | $62 |
| CSL Behring | 3 | $60 |
| BioCryst US Sales Co., LLC | 2 | $55 |
Products named: DUPIXENT, BREZTRI, NUCALA, CUVITRU, TRELEGY ELLIPTA, Xhance, Xolair, Rhapsido.
Industry payments across AZ — which companies pay providers there.
